Autopsy report · NCT02093468

Evaluation of MST-188 in Acute Lower Limb Ischemia

“Program discontinued to persue alternate indications.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Mast Therapeutics, Inc.

Sponsor type

Industry

Conditions

Acute Limb Ischemia

Interventions

MST-188; Saline

Participants

4

Sites

4

Countries

United States

Trials that died the same way

• LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
  “Clinical program was discontinued by Novartis” (67% match in meaning)
• RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
  “The sponsor's clinical program for the agent used in this study was discontinued.” (66% match in meaning)
• Utilization of MAsS in Patients Undergoing LT for HCC
  “Discontinued by Amra Medical due to funding.” (65% match in meaning)
• Developmental Correlates and Hormone Therapy Effects in Gender Dysphoria
  “the patients are now followed in another hospital. The study is discontinued” (65% match in meaning)
• Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Endodontics
  “Manufacturer discontinued drug before any participants could be enrolled.” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.